Updated just now · Live
Stock analysis, price data, and AI-powered insights for Whitehawk Therapeutics Inc (WHWK).
Whitehawk Therapeutics Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for WHWK.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). WHWK Stock Intelligence Report. [stoxpulse.com/stocks/whwk]
Disclaimer: The information on this page about Whitehawk Therapeutics Inc (WHWK) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Whitehawk Therapeutics Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Whitehawk Therapeutics Inc Presents Comprehensive ...
1d ago
Reported Sunday, Whitehawk Therapeutics Presents P...
1d ago
StoxPulse AI results for WHWK: Pulse Score 49.5/100. Primary sentiment trends from 5 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$194.0M
P/E Ratio
—
EPS
$-0.26
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Whitehawk Therapeutics Inc Presents Comprehensive Preclinical Data Highlighting Its Next-Generation Adc Portfolio At the Aacr 2026
Reported Sunday, Whitehawk Therapeutics Presents Preclinical Data For HWK-007, HWK-016 And HWK-206 Next-Generation ADC Portfolio At AACR 2026, Showing Tumor Regressions At Low Single-Digit Mg/Kg Doses
Whitehawk Therapeutics : Preclinical Assessment of HWK-016, a Next-Generation, MUC16-Targeting ADC with Novel Bioconjugation and Linker-Payload Technology
Whitehawk Therapeutics shares are trading higher after Citizens initiated its coverage on the stock with a Market Outperform rating and announced a price target of $8.
Citizens Initiates Coverage On Whitehawk Therapeutics with Market Outperform Rating, Announces Price Target of $8